DCGI Approved India’s First Intranasal Covid-19 Vaccine: Bharat Biotech

Andhra News, National News, News, Telangana News

Hyderabad: India’s first Intranasal Covid-19 vaccine approved for booster doses, which was manufactured by Bharat Biotech. According to the Hyderabad based Bharat Biotech company sources, the vaccine is available on the government’s CoWIN website. It will be available in the market by January-end for those above 18.

The company quoted a fixed price for the vaccine at Rs 800 per dose for the market and at Rs 325 for government hospitals. The iNCOVACC needle free vaccine-BBV154 got approval from the DCGI in November for restricted use in emergency for those above 18. The vaccine has been approved for mix-and-match usage (or heterologous vaccination), wherein a benecifiary may be administered shots of different Covid vaccines. Earlier this month, it was approved as heterologous booster dose.

The vaccine, iNCOVACC, is the world’s first intranasal vaccine for Covid to receive approval for the preliminary 2-dose schedule, the Hyderabad-based company had said. The Pharma giant’s executive chairman Dr Krishna Ella said, we have achieved the goals we set for ourselves during this pandemic. We have developed COVAXIN and iNCOVACC, two COVID vaccines from two different platforms with two other delivery systems.

The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics, Ella said. Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose 2-dose schedule; and a heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid vaccines in India.

The trials for the primary dose were conducted among 3,100 subjects in 14 trial sites across the country, while the heterologous booster dose was done at nine trial sites among 875 subjects. iNCOVACC is stable at 2-8°C for easy storage and distribution. Bharat Biotech has established extensive manufacturing capabilities at multiple sites across India, including in Gujarat, Karnataka, Maharashtra and Telangana.

Leave a Reply